Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
News|Articles|April 27, 2026
Raising Testicular Cancer Awareness Enhances Treatment Decision-Making and Survivorship Care
Author(s)Kyle Doherty
Fact checked by: Courtney Flaherty
Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.
Advertisement
Advertisement
Although 5-year relative survival rates remain high for patients with testicular cancer, early detection, continued advances in treatment approaches, and enhanced care for survivors are crucial to further improving outcomes for patients, according to Mina M. Fam, MD.
Related to this article
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
PDS Biotechnology will prioritize the IL-12 immunocytokine PDS0301 in metastatic colorectal cancer and pursue a partnership strategy for PDS0101.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Advertisement
Advertisement